Company: LNAI
Filing Date: 2025-09-29
Form Type: 10-K
Source: 0001731122-25-001316
Chunk: 1175

Company: Lunai Bioworks Inc.
Filing Date: 2025-09-29
Form: 10-K
Item: Item 1
Chunk 1175
---
 we may consider other strategic alternatives,
such as mergers, acquisitions, divestitures, joint ventures, partnerships and collaborations. We cannot be sure when or if any type of
transaction will result. Even if we pursue a transaction, such transaction may not be consistent with our stockholders’ expectations
or may not ultimately be favorable for our stockholders, either in the shorter or longer term.

Our growth prospects and the future
value of our Company are primarily dependent on the progress of our ongoing and planned development programs for our product candidates
as well as the outcome of our ongoing business development efforts and pipeline progression, together with the amount of our remaining
available cash. The development of our product candidates and the outcome of our ongoing business development efforts and pipeline are
highly uncertain. We expect to continue to reassess and make changes to our existing development programs and pipeline strategy. Our plans
for our development programs may be affected by the results of competitors’ clinical trials of product candidates addressing our
current target indications, and our business development efforts and pipeline progression may also be affected by the results of competitors’
ongoing research and development efforts. We may modify, expand or terminate some or all our development programs, clinical trials or
collaborative research programs at any time as a result of new competitive information or as the result of changes to our product pipeline
or business development strategy.

45

If serious adverse events
or other undesirable side effects or safety concerns attributable to our product candidates occur, they may adversely affect or delay
our clinical development and commercialization of some or all of our product candidates. 

Undesirable side effects or safety
concerns caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt our clinical trials and
could result in a more restrictive label or the delay or denial of regulatory approval. If treatment-related serious adverse events (“SAEs”)
or other undesirable side effects or safety concerns, or unexpected characteristics attributable to our product candidates are observed
in any future clinical trials, they may adversely affect or delay our clinical development and commercialization of the effected product
candidate, and the occurrence of these events could have a material adverse effect on our business and financial prospects. Results of
our future clinical trials could reveal a high and unacceptable severity and prevalence of adverse side effects. In such an event, our
trials could be suspended or terminated, and the FDA or other regulatory agency could order us to cease further development of or deny
approval of our product candidates for any or all targeted